Dynamics and persistence of CYP2D6 inhibition by paroxetine
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216224%3A14740%2F13%3A00065968" target="_blank" >RIV/00216224:14740/13:00065968 - isvavai.cz</a>
Alternative codes found
RIV/65269705:_____/13:#0002090
Result on the web
<a href="http://onlinelibrary.wiley.com/doi/10.1111/jcpt.12042/abstract" target="_blank" >http://onlinelibrary.wiley.com/doi/10.1111/jcpt.12042/abstract</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1111/jcpt.12042" target="_blank" >10.1111/jcpt.12042</a>
Alternative languages
Result language
angličtina
Original language name
Dynamics and persistence of CYP2D6 inhibition by paroxetine
Original language description
What is known and Objective Paroxetine is both a substrate and an inhibitor of CYP2D6. The objective of the presented study was to determine the persistence of CYP2D6 inhibition after short term (6 weeks) and long term (18,7 +/- 10,6 weeks) paroxetine treatment. Methods: Two the studies consisted of 30 depressive/anxiety patients each. In the first study, patients were subdivided into three groups treated with paroxetine (A1), alprazolam (A2) and paroxetine + alprazolam (A3). After 6 weeks, all the patients (A1+A2+A3) were switched to alprazolam treatment; metabolic activity was evaluated at the beginning, after 6 weeks of paroxetine/alprazolam/alprazolam + paroxetine treatment (A1/A2/A3) and 4 weeks after the switch to alprazolam treatment (Week 0, 6,10). In the second study patients on previous long term paroxetine treatment were subdivided into two groups treated with mirtazapine (B1) or paroxetine (B2); metabolic activity of CYP2D6 was evaluated at the beginning and after 6 weeks
Czech name
—
Czech description
—
Classification
Type
J<sub>x</sub> - Unclassified - Peer-reviewed scientific article (Jimp, Jsc and Jost)
CEP classification
FR - Pharmacology and apothecary chemistry
OECD FORD branch
—
Result continuities
Project
Result was created during the realization of more than one project. More information in the Projects tab.
Continuities
P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)
Others
Publication year
2013
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data specific for result type
Name of the periodical
JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS
ISSN
0269-4727
e-ISSN
—
Volume of the periodical
38
Issue of the periodical within the volume
4
Country of publishing house
US - UNITED STATES
Number of pages
7
Pages from-to
294-300
UT code for WoS article
000321339800006
EID of the result in the Scopus database
—